During the first six years of its operations, RTsafe has focused mainly on brain cancer. PseudoPatient, nominated as one of the 100 most technologically significant products in 2019, is the personalized care solution that RTsafe has developed, patented and commercialized for brain tumor patients, following extensive R&D and tens of scientific publications. It is a 510k-FDA cleared solution that is already contributing to the safety and effectiveness of radiotherapy treatments globally – in a totally personalized way.

Our next core milestones are to make our personalized quality assurance solutions easily accessible to millions of cancer patients globally and to keep innovating and developing equivalent solutions for cancer types other than brain tumors.

At RTsafe, our goal is to develop and implement high-end technologies to achieve maximum treatment efficiency combined with maximum patient safety, allowing the patient to return to life’s activities, following an effective treatment.

Whatever role you play in the treatment cycle, RTsafe’s products and services can help you. Click on the button below to learn more about the benefits we can bring to you and your colleagues.